Drug Database
Back to search

Japan· JP-1319746Q1010

レボカバスチン塩酸塩

A levocabastine product containing レボカバスチン塩酸塩, registered in Japan, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.

On Japan’s NHI price listATC R01AC02

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedレボカバスチン塩酸塩ATCR01AC02REGISTER NO.JP-1319746Q1010PACKS LISTED0CHECKEDSeptember 25, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about レボカバスチン塩酸塩Answers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Levocabastine is registered in 10 of 19 countries.

Countries holding a registration under ATC R01AC02 (levocabastine), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 6 of them publish a price we can compare per daily dose
Search levocabastine products by name

Levocabastine · ATC R01AC02

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

MHLW / PMDA (Japan)
Active substance
レボカバスチン塩酸塩
Manufacturer
—
Country
Japan (JP)
ATC code
R01AC02
ATC class
Levocabastine
Defined daily dose
0.6 mg, N
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same class

Other records under R01AC02

Levocabastine, as other registers publish it.

All levocabastine products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ee825faf-e1ad-436d-a5cd-3533a17cd82a
GET /v1/drugs/ee825faf-e1ad-436d-a5cd-3533a17cd82a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "０．０２５％１ｍＬ",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "1319746Q1010",
  "category": "外用薬",
  "price_yen": 41.8,
  "generic_name": "レボカバスチン塩酸塩",
  "product_name_jp": null,
  "therapeutic_class": "1319",
  "transitional_expiry": null
}
API referenceMCP serverPlans

See everything about levocabastine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console